Paper Details

  1. Home
  2. Paper Details

Neuroprotective Effects of Sodium Butyrate and Monomethyl Fumarate Treatment through GPR109A Modulation and Intestinal Barrier Restoration on PD Mice.

Author: DingSong-Tao, JianYu-Xin, LeiYi-Han, LiuHan-Deng, LiuMing-Ran, MiaoWen-Teng, XuJing-Yi, XuRui-Chen, XuWen-Xin, YanNing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the effects of sodium butyrate (NaB) and monomethyl fumarate (MMF), agonists of G-protein-coupled receptor 109A (GPR109A), on Parkinson's disease (PD) in mice. Both NaB and MMF ameliorated motor symptoms and pathological changes in PD mice by restoring the intestinal barrier.
Paper Details　
Original Abstract of the Article :
Research has connected Parkinson's disease (PD) with impaired intestinal barrier. The activation of G-protein-coupled receptor 109A (GPR109A) protects the intestinal barrier by inhibiting the NF-κB signaling pathway. Sodium butyrate (NaB), which is a GPR109A ligand, may have anti-PD effects. The cur...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571500/

データ提供：米国国立医学図書館（NLM）

Parkinson’s Disease: A Gut Feeling

The world of Parkinson’s disease (PD) is complex and multifaceted. This study explores a new avenue for understanding and treating this debilitating disease by investigating the role of the intestinal barrier. It’s like discovering a hidden oasis in the vast desert of PD research, revealing a new source of hope.

Gut Health as a Key to PD Treatment

This research suggests that restoring the intestinal barrier may hold the key to ameliorating PD symptoms. It explores the potential of GPR109A activation, achieved through sodium butyrate (NaB) or monomethyl fumarate (MMF) treatment, as a promising therapeutic approach. It’s like uncovering a hidden wellspring of potential in the desert of PD research, offering a new source of water for healing.

From Gut to Brain: A Journey of Recovery

This study highlights the interconnectedness of the gut and brain, emphasizing the importance of gut health in neurological conditions. It offers a hopeful message for individuals living with PD, suggesting that restoring the gut barrier may be a crucial step in the journey toward recovery. Think of it as a caravan of healing, traveling from the gut to the brain, carrying the promise of restoration.

Dr. Camel's Conclusion

This research offers a compelling and promising new direction for PD treatment. It reveals the potential of targeting the gut barrier to unlock new therapeutic possibilities. The findings hold out the hope of a new oasis in the desert of PD, a beacon of hope for a brighter future.
Date :
  1. Date Completed 2022-10-17
  2. Date Revised 2022-10-19
Further Info :

Pubmed ID

36235813

DOI: Digital Object Identifier

PMC9571500

Related Literature

Article Analysis
・Effects of monomethyl fumarate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.